Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gensia Sicor propofol

Executive Summary

Baltimore federal court finds that FDA appropriately approved Gensia Sicor's generic propofol despite the use of a different preservative than that used in Zeneca's Diprivan. The Aug. 11 ruling grants the company and FDA's motion for summary judgment in a suit brought by Zeneca in February that sought reversal of FDA's approval of the propofol ANDA. Zeneca had argued that FDA's therapeutic equivalence rating for the generic propofol was inappropriate given "substantial" labeling differences between the products (1"The Pink Sheet" Feb. 15, p. 22). Zeneca said it is considering an appeal

You may also be interested in...



AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA

AstraZeneca must issue a "Dear Healthcare Provider" letter clarifying misleading information regarding generic propofol found in its promotional materials for the anesthetic Diprivan, an FDA warning letter states.

AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA

AstraZeneca must issue a "Dear Healthcare Provider" letter clarifying misleading information regarding generic propofol found in its promotional materials for the anesthetic Diprivan, an FDA warning letter states.

Generic Propofol Label Differences Argue Against "AB" Rating, Zeneca Says

"Substantial" differences in the labeling of Gensia Sicor's generic version of Diprivan (propofol) do not support the therapeutic equivalence rating the drug has been given by FDA, Zeneca asserted.

Related Content

UsernamePublicRestriction

Register

PS034675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel